Opthea Limited

Short Term Long Term Short Term Comparison Long Term Comparison
  • OPT
  • 1d-4.17%
  • 1w-7.38%
  • 1m12.20%
  • 1y8.44%
ATH
  • ATH Price$4.92
  • ATH Date2000-03-09
  • % since ATH-85.97%
  • % to ATH612.71%
ATL
  • ATL Price$0.13
  • ATL Date2015-05-21
  • % from ATL422.73%
  • Last Low Price$0.132
  • Last Low Date2015-05-21
  • % From Last Low422.73%
IPO
  • IPO Price$0.27
  • % Current ROI USD255.56%
  • ATH Price$4.92
  • % ROI ATH 372,553.03%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="OPT"]

Key Data [addtoany]

Current price $0.69
Sector Healthcare
Industry Biotechnology
Today's High/Low $0.715/$0.685
Volume 451,013.00
Previous Close $0.72
52 Week High/Low $0.815/$0.312
Market Cap 477,221,056.00
P/E Ratio 0
Forward P/E 1 Yr. $6.75
Earnings Per Share(EPS) $-0.22
Annualized Dividend $0
$0.69
[addtoany]

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia.
The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema.
The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Annual Data | Millions of US $ except per share data 2019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
Cash on hand --------------------
Receivables $14.93$12.41$3.22$1.81$3.35$2.71$2.32$1.66$0.21$0.36$0.48$0.54$0.31$0.11$0.24$0.09$0.10$0.06$0.25$0.11
Inventory --------------------
Pre-Paid Expenses --------------------
Other Current Assets -$0.29$2.71$1.59$0.14$0.11$0.14$0.07$0.08$0.07$0.11$0.32$0.19$13.69$0.20$0.26$0.08$0.03$0.02$0.03
Total Current Assets $36.89$45.21$55.33$16.65$21.92$9.98--------------
Property, Plant, And Equipment $0.05$0.07$0.06$0.09$0.11$0.15$0.08$0.11$0.10$0.05$0.07$0.08$0.08$0.05$0.04$0.05$0.07$0.08$0.10$0.09
Long-Term Investments $0.71$0.79$1.15$0.32$2.04$2.28--------------
Goodwill And Intangible Assets -------------$0.15$0.20-----
Other Long-Term Assets -----$0.06$0.08$0.18$0.19$0.05$0.15$0.42$0.19$1.23-$1.09$0.69$0.82-$0.08
Total Long-Term Assets $0.77$0.86$1.21$0.41----------------
Total Assets $37.66$46.08$56.54$17.05$24.07$12.46$16.41$22.61$24.50$34.67$41.28$53.85$66.86$59.01$43.17$42.14$36.86$41.72$47.75$25.49
Total Current Liabilities $6.52$7.86$2$2.01$2.25$1.77$1.91$2.13$2.44$2.66$2.33$1.79$3.11$1.31$5.60$0.43$0.46$0.19$0.19$0.29
Long Term Debt --------------------
Other Non-Current Liabilities $0.02$0.04$0.05$0.06$0.10$0.16$0.07$0.11$0.05$0.04$0.02$0.01$0.03$0.04$0.03$0.02$0.02$0.18$0.13$0.07
Total Long Term Liabilities $0.02$0.04$0.05$0.06----------------
Total Liabilities $6.54$7.90$2.05$2.07$2.35$1.98$2.05$2.41$2.68$2.85$2.51$2.45$5.89$2.32$5.63$0.45$0.47$0.37$0.33$0.37
Common Stock Net $113.02$98.40$97.85$53.84$53.84$39.45$39.45$39.40$38.37$38.37$38.37$33.17$33.17$33.17$33.17$48.40$48.89$50.35$50.23$26.81
Retained Earnings (Accumulated Deficit) $-86.06$-65.15$-48.25$-42.05$-28.38$-23.24----$3.97$13.88$15.03$3.83$2.84-----
Comprehensive Income --------------------
Other Share Holders Equity $4.16$4.92$4.89$3.19$-4.56$-6.68--------------
Share Holder Equity $31.12$38.17$54.49$14.98$20.90$9.54$13.45$18.91$21.82$31.82$38.75$47.43$55.85$56.59$37.40$41.70$36.38$41.35$46.98$25.12
Total Liabilities And Share Holders Equity --------------------